Overview

Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Status:
Completed
Trial end date:
2019-01-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of bexagliflozin compared to placebo as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
Phase:
Phase 3
Details
Lead Sponsor:
Theracos
Treatments:
Bexagliflozin
Metformin